Every year, CMED (Camara de Regulacao do Mercado de Medicamentos) publishes its annual update to pharmaceutical price ceilings in Brazil. For independent pharmacies, this update is one of the most practically important regulatory events of the year: it sets the maximum price that any link in the supply chain, from manufacturer to distributor to pharmacy, can charge for regulated medications.
The 2026 update came into effect in the first quarter of the year. This article explains the mechanics of how the CMED system works, what changed in 2026, and what the practical implications are for independent pharmacy procurement.
How CMED Price Regulation Works
Brazil's pharmaceutical price regulation system is administered by CMED, an inter-ministerial body with participation from the Ministries of Health, Finance, Justice, and Development. The core mechanism is the Preco Maximo ao Consumidor (PMC), the maximum consumer price, and the Preco Fabrica (PF), the factory price that serves as the basis for the entire pricing chain downstream.
Distributors buy from manufacturers at prices derived from PF and sell to pharmacies at prices that must not exceed the allowed maximum at each stage. Pharmacies resell to the public at prices that must not exceed the PMC. These are ceilings, not mandated prices: the actual transaction price can be anywhere below the ceiling, and in practice, especially for generics, competition pushes actual prices well below CMED maxima.
The annual update adjusts these ceilings using an index called the IPCA (Indice Nacional de Precos ao Consumidor Amplo) as a primary input, along with sector-specific adjustments that can differ by product category. Some categories receive different adjustment factors based on CMED's assessment of market dynamics in that category.
What the 2026 Update Changed
The 2026 adjustment reflected the IPCA trajectory from the preceding 12-month period. For most categories, the adjustment represented a single-digit percentage increase in the official ceilings. The increase for reference medications (medicamentos de referencia) was somewhat higher than for generics, which is consistent with CMED's general policy of protecting price competitiveness in the generic segment.
For pharmacy procurement, the practical impact of a ceiling increase depends on how close actual transaction prices were to the ceiling before the update. For reference medications, where brand-based differentiation allows manufacturers to price closer to the ceiling, an increase in the ceiling can translate more directly into a corresponding increase in what distributors charge. For generics, where actual prices are often significantly below the ceiling, the ceiling increase has less direct effect on what you actually pay.
The more important change for independent pharmacies in 2026 was the updated product list: CMED's annual publication includes changes to which products are regulated and how they are classified. Products can move between reference, generic, and similar classifications as regulatory status changes, which affects what CMED tier applies to them. In 2026, several products that had been launching generics now have established generic status, which affects both the applicable ceiling and the competitive dynamics in that product category.
Reading a CMED Table
The CMED annual publication is available on the ANVISA website and runs to thousands of rows. Navigating it efficiently requires understanding the column structure. The key columns for a pharmacy buyer are the CNPJ of the manufacturer, the product name and concentration, the presentation (how many units per package), the PF value (factory price), and the PMC values differentiated by state-level ICMS rates.
Brazil's pharmaceutical pricing is complicated by the fact that the applicable ICMS rate varies by state. CMED publishes separate PMC columns for different ICMS brackets. In Sao Paulo, the relevant column depends on the current ICMS rate applicable to pharmaceutical products in SP. A pharmacy in SP reading the CMED table should use the PMC(SP) column rather than a national average.
What matters for procurement is not the PMC (the maximum you can charge consumers) but the maximum price at which you can be billed by your distributor, which is governed by the distributor's own margin limits within the PF-to-PMC chain. If a distributor quotes you a price above the allowed distributor margin on a regulated product, that is not only commercially unfavorable: it may represent a pricing violation that CMED can investigate. Knowing the CMED reference values gives you a sanity check on distributor quotes.
How This Affects Procurement Decisions
The 2026 ceiling update has two practical effects on procurement decisions for independent pharmacies. First, on products where reference medication prices moved up significantly, the comparison between reference and generic becomes more favorable to generics in terms of purchase cost. Pharmacies already focused on generics for their stock will not see much change here, but pharmacies that still carry significant reference medication volume may find the cost differential more pronounced now.
Second, on products with newly confirmed generic status, expect more distributors to carry the generic and more price competition among them. The first year after a product establishes a robust generic market in Brazil is often when the price spread between distributors is widest, as different distributors have bought from different generic manufacturers at different prices and are working through their inventories. This is exactly the kind of situation where having price visibility across multiple distributors at the same time is most valuable.
What This Means If You Use a Procurement Platform
Procurement platforms that show real-time distributor prices are operating within the CMED framework. Every price shown should be at or below the applicable CMED ceiling. If a platform shows a price that exceeds the CMED ceiling for a given product in your state, that is a data quality problem that the platform operator needs to address.
On Covalenty, distributor-listed prices are required to be CMED-compliant. We do not serve as the CMED compliance enforcement authority: that is CMED's and ANVISA's role. But we do use CMED reference values as one input in validating that prices in our catalog fall within a reasonable range. If a price looks anomalous relative to CMED data, it gets reviewed before it is shown to buyers.
The CMED tables also help pharmacies understand which products have meaningful price variation worth comparing. Products priced well below the ceiling across all distributors have limited upside from comparison shopping. Products that distributors tend to price closer to the ceiling have more variation and more potential benefit from a systematic comparison.
Finding the Official Data
The authoritative source for CMED price tables is the ANVISA website at anvisa.gov.br. The data is published in spreadsheet format and updated according to the annual cycle. For independent pharmacies that want to cross-reference a distributor quote against the official ceiling, this is the right place to look. The table can be cumbersome to navigate, but ANVISA makes it publicly available and regularly updated.
We are not saying that every pharmacy needs to audit every distributor quote against the CMED table line by line. That would not be a practical use of time. The more useful approach is to understand which product categories and which price bands are regulated tightly versus loosely, and to use that knowledge as a rough framework for evaluating whether a quoted price is in the expected range.
